Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time
In first-of-its-kind prospective analysis, patients switching from prior prophylactic treatment to donidalorsen experienced further reductions in mean monthly HAE attack rates from baseline
Donidalorsen demonstrated a favorable safety and tolerability profile across all cohorts
Data to be presented today at EAACI Congress 2024
Ionis to host webcast on Friday, May 31 at 8:00am ET
Webcast
Ionis will hold a webcast today at 8:00am ET to discuss this update. Interested parties may access the webcast here. A webcast replay will be available for a limited time.
Ionis will hold a webcast today at 8:00am ET to discuss this update. Interested parties may access the webcast here. A webcast replay will be available for a limited time.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.